Abstract

BackgroundPrevious researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and summarize its possible tumor-related mechanisms.MethodsThe available databases were searched for eligible studies that evaluated the clinicopathological and prognostic roles of TRIM44 in patients with malignancies. The hazard ratios (HR) and odds ratios (OR) were combined to assess the predictive role of TRIM44 using Stata/SE 14.1 software.ResultsA total of 1740 patients from thirteen original studies were finally included in this study. The results of the combined analysis showed that over-expression of TRIM44 protein was significantly correlated with shorter overall survival (OS) (HR = 1.94, 95% CI: 1.60–2.35) and worse disease-free survival (DFS) (HR = 2.13, 95% CI: 1.24–3.65) in cancer patients. Additionally, the combined ORs indicated that elevated expression level of TRIM44 protein was significantly associated with lymph node metastasis (OR = 2.69, 95% CI: 1.71–4.24), distant metastasis (OR = 10.35, 95% CI: 1.01–106.24), poor tumor differentiation (OR = 1.78, 95% CI: 1.03–3.09), increased depth of tumor invasion (OR = 2.72, 95% CI: 1.73–4.30), advanced clinical stage (OR = 2.75, 95% CI: 2.04–3.71), and recurrence (OR = 2.30, 95% CI: 1.34–3.95). Furthermore, analysis results using Gene Expression Profiling Interactive Analysis (GEPIA) showed that the expression level of TRIM44 mRNA was higher in most tumor tissues than in the corresponding normal tissues, and the relationship between TRIM44 mRNA level and prognosis in various malignant tumors also explored in GEPIA and OS analysis webservers.ConclusionsTRIM44 may serve as a valuable prognostic biomarker and a potential therapeutic target for patients with malignancies.

Highlights

  • Previous researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors

  • Inclusion and exclusion criteria Inclusion criteria were as follows: 1) The expression of TRIM44 protein was measured in tissue samples from primary solid cancers; 2) All patients included in the original studies were divided into two groups according to the expression levels of TRIM44 protein; 3) The hazard ratio (HR) of survival outcomes or clinicopathological data based on the high and low levels of TRIM44 protein expression was reported; 4) The survival curve presented or sufficient data were available for calculating the hazard ratios (HR) with 95% CI

  • The correlation between increased TRIM44 expression and overall survival (OS) Eleven studies involving 1547 malignancy patients reported the HRs for OS

Read more

Summary

Introduction

Previous researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and summarize its possible tumor-related mechanisms. Advances in detection techniques have contributed to the discovery of early cancer, and the progress of perioperative treatment has reduced the mortality in patients with malignancies. Due to the ongoing intensive cancer research, the precise tumor-related mechanisms have gradually been understood and an increasing number of therapeutic targets have been identified. Major efforts have been made to identify molecular markers that predict the prognosis. These markers can often be used as therapeutic targets, and the corresponding targeted drug design can be carried out. The current targeted drug design for functional proteins may be more conducive to bringing new progress in tumor therapy

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.